Image-based evaluations of distribution and cytotoxicity of Irinotecan (CPT-11) in a multi-compartment micro-cell coculture deviceNAKAYAMA, Hidenari; KIMURA, Hiroshi; FUJII, Teruo et al.Journal of bioscience and bioengineering. 2014, Vol 117, Num 6, pp 756-762, issn 1389-1723, 7 p.Article

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese : roles of UGT1A1*6 and *28MINAMI, Hironobu; SAI, Kimie; SHIRAO, Kuniaki et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 7, pp 497-504, issn 1744-6872, 8 p.Article

Mechanisms of resistance to topoisomerase I-targeting drugsRASHEED, Zeshaan A; RUBIN, Eric H.Oncogene (Basingstoke). 2003, Vol 22, Num 47, pp 7296-7304, issn 0950-9232, 9 p.Article

Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patientsXIAOQIANG XIANG; RAO JADA, Srinivasa; ENG HUAT TAN et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 9, pp 683-691, issn 1744-6872, 9 p.Article

Metabolism of irinotecan (CPT-11) by human hepatic microsomes : Participation of cytochrome P-450 3A and drug interactionsHAAZ, M.-C; RIVORY, L; RICHE, C et al.Cancer research (Baltimore). 1998, Vol 58, Num 3, pp 468-472, issn 0008-5472Article

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecanVAN ERP, Nielka P. H; BAKER, Sharyn D; MING ZHAO et al.Clinical cancer research. 2005, Vol 11, Num 21, pp 7800-7806, issn 1078-0432, 7 p.Article

Irinotecan in combination with new agentsVANHOEFER, U; ROUGIER, P; BORNER, M et al.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 7, pp 14-20, issn 1359-6349, 7 p.Conference Paper

Salvage chemotherapy With CPT-11 for recurrent meningiomaCHAMBERLAIN, Marc C; TSAO-WEI, Denice D; GROSHEN, Susan et al.Journal of neuro-oncology. 2006, Vol 78, Num 3, pp 271-276, issn 0167-594X, 6 p.Article

Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d'une étude multicentrique de l'Anocef = Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas : Preliminary results of an ANOCEF Multicenter StudyGUIU, S; TAILLIBERT, S; CAPELLE, F et al.Revue neurologique (Paris). 2008, Vol 164, Num 6-7, pp 588-594, issn 0035-3787, 7 p.Article

Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomesDICKO, Awa; TARDI, Paul; XIAOWEI XIE et al.International journal of pharmaceutics. 2007, Vol 337, Num 1-2, pp 219-228, issn 0378-5173, 10 p.Article

Insights, challenges, and future directions in irinogeneticsTAE WON KIM; INNOCENTI, Federico.Therapeutic drug monitoring. 2007, Vol 29, Num 3, pp 265-270, issn 0163-4356, 6 p.Article

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly scheduleGARCIA, Agustin A; PUJARI, Mahesh; JEFFERS, Susan et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 1, pp 75-82, issn 0344-5704, 8 p.Article

Effects of green tea compounds on irinotecan metabolismMIRKOV, Snezana; KOMOROSKI, Bernard J; RAMIREZ, Jacqueline et al.Drug metabolism and disposition. 2007, Vol 35, Num 2, pp 228-233, issn 0090-9556, 6 p.Article

5-fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome : report of a caseSTEINER, M; SEULE, M; STEINER, B et al.Journal of clinical pathology. 2005, Vol 58, Num 5, pp 553-555, issn 0021-9746, 3 p.Article

Irinotecan drug eluting beads for use in chemoembolization : In vitro and in uiuo evaluation of drug release propertiesTAYLOR, Rachel R; YIQING TANG; GONZALEZ, M. Victoria et al.European journal of pharmaceutical sciences. 2007, Vol 30, Num 1, pp 7-14, issn 0928-0987, 8 p.Article

Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solutionOZDEMIR, Filiz Arioz; ANILANMERT, Beril; PEKIN, Mursit et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 5, pp 529-534, issn 0344-5704, 6 p.Article

Pharmacogenomics: road to anticancer therapeutics nirvana?DESAI, Apurva A; INNOCENTI, Federico; RATAIN, Mark J et al.Oncogene (Basingstoke). 2003, Vol 22, Num 42, pp 6621-6628, issn 0950-9232, 8 p.Article

Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft modelsMATSUZAKI, Takeshi; TAKAGI, Akimitsu; FURUTA, Tomio et al.Oncology reports. 2012, Vol 27, Num 1, pp 189-197, issn 1021-335X, 9 p.Article

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerSPIGEL, David R; GRECO, F. Anthony; RUBIN, Mark S et al.Lung cancer. 2012, Vol 77, Num 2, pp 359-364, issn 0169-5002, 6 p.Article

Association of carboxylesterose 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patientsSAI, Kimie; SAITO, Yoshiro; YAMAMOTO, Noboru et al.British journal of clinical pharmacology. 2010, Vol 70, Num 2, pp 222-233, issn 0306-5251, 12 p.Article

Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin™) for preventing delayed diarrheaHIDAKA, Muneaki; YAMASAKI, Keishi; OKUMURA, Manabu et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 3, pp 321-328, issn 0344-5704, 8 p.Article

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenibMROSS, K; STEINBILD, S; BAAS, F et al.European journal of cancer (1990). 2007, Vol 43, Num 1, pp 55-63, issn 0959-8049, 9 p.Article

Irinotécan et dysfonctions hépatiques : Optimisation des traitements anticancéreux de l'enfant et de l'adulte = Irinotecan and liver dysfunctionsSABLIN, Marie-Paule; LE TOURNEAU, Christophe; FAIVRE, Sandrine et al.Thérapie (Paris). 2007, Vol 62, Num 2, pp 111-115, issn 0040-5957, 5 p.Conference Paper

A phase I study of irinotecan administered on a weekly schedule in pediatric patientsBOMGAARS, L; KERR, J; BERG, S et al.Pediatric blood & cancer. 2006, Vol 46, Num 1, pp 50-55, issn 1545-5009, 6 p.Article

Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicityKITAGAWA, Chiyoe; ANDO, Maki; ANDO, Yuichi et al.Pharmacogenetics (London). 2005, Vol 15, Num 1, pp 35-41, issn 0960-314X, 7 p.Article